MiMedx Group (NASDAQ:MDXG – Get Free Report) is projected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect MiMedx Group to post earnings of $0.07 per share and revenue of $89.42 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
MiMedx Group Price Performance
NASDAQ MDXG opened at $7.95 on Tuesday. The firm’s fifty day simple moving average is $8.81 and its two-hundred day simple moving average is $7.67. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The firm has a market capitalization of $1.17 billion, a P/E ratio of 14.45 and a beta of 1.94.
Analysts Set New Price Targets
Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.00.
MiMedx Group Company Profile
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Featured Articles
- Five stocks we like better than MiMedx Group
- Investing In Automotive Stocks
- Finding Hidden Gems: Unconventional Penny Stock Investing
- What is Insider Trading? What You Can Learn from Insider Trading
- Price Targets on NVIDIA Rise in Front of Earnings
- What is the NASDAQ Stock Exchange?
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.